RxDoctor Payments Data

Robin Strahl

Family · Richland, INNPI 1932693330

Payments from drug & device makers

$2,011in general payments, 2019–2025

Across 120 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Myriad Women's Health, Inc.$196
  • Amgen$107
  • Novo Nordisk$70
  • Lilly USA, LLC$64
  • Biohaven Pharmaceuticals, Inc.$60
  • plus $347 from 12 others

What the payments were for

  • Food & beverage$2,011100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,011 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$10,857
Medicare patients
49
Services billed
252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$19,378
JardianceEmpagliflozin12$9,212
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,527
Entacapone11$685
Albuterol Sulfate HfaAlbuterol Sulfate18$612
Amitriptyline Hcl15$551
Gabapentin26$534
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$427
Sucralfate16$376
Bupropion XlBupropion Hcl17$376
Omeprazole33$228
Prednisone27$221
Levothyroxine Sodium27$219
Buspirone Hcl17$218
Atorvastatin Calcium38$192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$70$19,37821 claims
Boehringer IngelheimJardiance$32$9,21212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.

Other family in Richland

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →